Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TET2 mutant N/A angioimmunoblastic T-cell lymphoma not applicable detail...
DNMT3A mutant N/A angioimmunoblastic T-cell lymphoma not applicable detail...
IDH2 mutant N/A angioimmunoblastic T-cell lymphoma not applicable detail...
IDH1 mutant N/A angioimmunoblastic T-cell lymphoma not applicable detail...
TET2 T1063Nfs*5 TET2 E1207K Dasatinib angioimmunoblastic T-cell lymphoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02232516 Phase II Lenalidomide + Romidepsin Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma Active, not recruiting USA 0
NCT02689453 Phase I Alemtuzumab + rhIL-15 Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Completed USA 0
NCT03017820 Phase I VSV-hIFNbeta-NIS VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma Recruiting USA 0
NCT03049449 Phase I ATLCAR.CD30 cells Cyclophosphamide + Fludarabine T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Completed USA 0
NCT03081910 Phase I CD5 CAR T cells Cyclophosphamide + Fludarabine Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) Recruiting USA 0
NCT03372057 Phase II Duvelisib A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) Completed USA | ITA | GBR | DEU 0
NCT03586999 Phase Ib/II Cyclophosphamide + Doxorubicin + Etoposide + Nivolumab + Prednisone + Vincristine Sulfate Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas Active, not recruiting USA 0
NCT03590574 Phase Ib/II AUTO4 Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma Recruiting GBR | ESP 0
NCT03719105 Phase I Pembrolizumab Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Pralatrexate + Prednisone Calaspargase pegol-mknl + Dexamethasone + Etoposide + Ifosfamide + Methotrexate Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma Recruiting USA 0
NCT03829540 Phase I CD4CAR CD4CAR for CD4+ Leukemia and Lymphoma Recruiting USA 0
NCT03900442 Phase I GGTI-2418 Phase 1 Study of PTX-100 in Patients With Advanced Malignancies Unknown status AUS 0
NCT03902184 Phase II Gemcitabine + Lacutamab + Oxaliplatin Lacutamab IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK) Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT 1
NCT04018248 Phase I BR101801 BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) Active, not recruiting USA 1
NCT04234048 Phase I Fenretinide Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT04334174 Phase II Brentuximab vedotin Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas (BRENTICON-T) Withdrawn USA 0
NCT04569032 Phase II Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression Active, not recruiting USA | ITA | GBR | FRA | ESP 1
NCT04639843 Phase I Azacitidine + Doxorubicin + Duvelisib + Romidepsin Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma Withdrawn USA 0
NCT04703192 Phase II DS-3201b Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 3
NCT04747236 Phase II Pralatrexate Belinostat Azacitidine + Romidepsin Gemcitabine Romidepsin A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL) Recruiting USA 0
NCT04771572 Phase I LP-118 Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. Recruiting USA 0
NCT04795869 Phase II Brentuximab vedotin + Pembrolizumab Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma Withdrawn USA 0
NCT04803201 Phase II Cyclophosphamide + Doxorubicin + Duvelisib + Etoposide + Prednisone + Vincristine Sulfate Azacitidine + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Vincristine Sulfate Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma Recruiting USA 0
NCT04984837 Phase II Gemcitabine + Oxaliplatin Gemcitabine + Lacutamab + Oxaliplatin Study of Lacutamab in Peripheral T-cell Lymphoma Recruiting FRA | ESP | DEU | BEL 0
NCT05010005 Phase I Duvelisib + Ruxolitinib A Study of Ruxolitinib and Duvelisib in People With Lymphoma Active, not recruiting USA 0
NCT05079282 Phase I ONO-4685 Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma Recruiting USA 0
NCT05138458 Phase Ib/II Cyclophosphamide + Fludarabine + MT-101 MT-101 A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL (IMAGINE) Suspended USA 0
NCT05274997 Phase II Linperlisib A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma Unknown status USA 0
NCT05371054 Phase Ib/II Prednisone + Venetoclax + VIP152 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Recruiting USA 0
NCT05377827 Phase I WU-CART-007 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies Recruiting USA 0
NCT05883449 Phase II AB-101 + AFM13 Aldesleukin Cyclophosphamide + Fludarabine Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL (LuminICE-203) Recruiting USA 0
NCT05967416 Phase I SIRPant-M Phase 1, Open-Label Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma Recruiting USA 0
NCT05983965 Phase I Tazemetostat Acalabrutinib + Tazemetostat Study of Tazemetostat in Lymphoid Malignancies Not yet recruiting USA 0
NCT06072131 Phase III Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate Cyclophosphamide + Pralatrexate + Prednisone + Vincristine Sulfate Belinostat + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL (CRESCENDO) Recruiting USA 0
NCT06393738 Phase I ARV-393 A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. Recruiting USA | ESP 0